Gelonghui November 1st 丨Changjiang Life Technology (00775.HK)It was announced that at the annual meeting of the Society of Cancer Immunotherapy to be held in San Diego, California, USA on November 4, 2023, the company will present pre-clinical research data on the dual antigen cancer vaccine being developed for both melanoma priority antigen (PRAME) and cytostatic death-ligand 1 (PD-L1).
The cancer vaccine in this preclinical study contains PRAME and PD-L1 antigen sequences to induce an anti-cancer immune response. PRAME is a cancer antigen commonly found in many different types of cancer and is related to various carcinogenic processes. PD-L1 is one of the most important immune checkpoint antigens highly present in cancer cells, and can inhibit the immune response of T cells in the tumor microenvironment.
In preclinical research, the company also investigated whether the PRAME and PD-L1 biantigen cancer vaccines can have preventive and therapeutic effects in inhibiting tumor growth when applied to a mouse model of homologous hepatocarcinoma cells in situ. Data from preclinical studies show that in cancer immunotherapy, a protein fusion vaccine can simultaneously trigger immune responses against PRAME and PD-L1.
The company believes that the preclinical efficacy results of the PRAME and PD-L1 biantigen cancer vaccines against liver cancer are encouraging, and the company expectsuntoClinical trials can be carried out in the next few years. ByuntoLiver cancer is the second leading cause of cancer death in Asia, and there is still a major medical need to be addressed. The company plans to further study the PRAME and PD-L1 dual antigen cancer vaccine pairsuntoThe effects of liver cancer and other cancers that excessively present PRAME and PD-L1 antigens.